Paolo Bosani
Managing Partner at Expand Capital Partners
Switzerland
Paolo Bosani, Managing Partner at Expand Capital Partners is an active investor based in Switzerland. This profile covers what Paolo Bosani backs, at which stage, and how founders can reach out in 2026.
Paolo Bosani is the Managing Partner at Expand Capital Partners.
- Investor type
- VC
- Stages
- SeedSeries A
- Invests in
- Fintech
- Location
- Switzerland
- Typical check
- $625K
How to reach Paolo Bosani
Angels and operators like Paolo Bosani reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Paolo Bosani
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Paolo Bosani invest in?
Paolo Bosani invests in Fintech, typically at Seed and Series A. Match your sector and stage, then reach out with a personalized pitch.
What stage does Paolo Bosani invest at?
Paolo Bosani typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Paolo Bosani's typical check size?
Paolo Bosani typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Paolo Bosani?
Unlock Paolo Bosani's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.